课题基金 / 基金详情

TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE

TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE
TAK 603/A 165646 用于克罗恩病患者
批准号：
6263881
负责人：
KIM L ISAACS
金额：
$0.02万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263881
关键词：
Crohn's disease antirheumatic agents antiulcer drug clinical research drug screening /evaluation gastrointestinal agents gastrointestinal disorder chemotherapy human subject human therapy evaluation immunomodulators quinoline

项目摘要

项目成果

KIM L ISAACS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a Phase II study of the safety and efficacy of TAK-603/A-165646 in patients with crohn's disease. The primary efficacy endpoint of this study will be a percentage of patients achieving remission, defined as a CDAI score of 150 or less. Secondary endpoints will include percentage of patients achieving improvement in symptions, indicated by a reduction in baseline CDAI by at least 50 points, percentage of patients classified as treatment failure, and changes in physicians global assessment of disease activity, patients global assessment of disease activity, laboratory measure of inflammatory activity and qualify of life evaluations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: MULTI-SITE TRIAL OF AZATHIOPRINE DOSING IN CROHN'S DISEASE
MULTI-SITE TRIAL OF AZATHIOPRINE DOSING IN CROHN'S DISEASE
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE
海外基金